



THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, NEW ZEALAND OR IN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION. UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS SHALL THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION.

C4X Discovery Holdings plc
("C4XD" or the "Company")

**Result of General Meeting and Open Offer
and
Issue of Equity**

C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces that at the General Meeting held earlier today in connection with the Company's Placing, Subscription and Open Offer, details of which were announced on 24 October 2019, all resolutions put to shareholders were duly passed.

The Company also announces that it has received valid acceptances in respect of 3,907,141 Open Offer Shares from Eligible Shareholders, including applications under the Excess Application Facility. This represents approximately 60.85 per cent. of the 6,421,404 Open Offer Shares offered.

Following the passing of the resolutions at the General Meeting, and conditional on First Admission and Second Admission, the Company has raised £7.59 million (before expenses) in aggregate through the Placing, Subscription and Open Offer.

Applications have been made for the 46,466,667 Placing Shares, 200,000 Subscription Shares and the 3,907,141 Open Offer Shares to be admitted to trading on AIM. It is expected that First Admission of 25,143,330 EIS/VCT Shares will take place at 8.00 a.m. on 14 November 2019 and Second Admission of 21,323,337 General Placing Shares, 200,000 Subscription Shares and 3,907,141 Open Offer Shares will take place at 8.00 a.m. on 15 November 2019. The Placing Shares, Subscription Shares and Open Offer Shares will rank *pari passu* with the Existing Ordinary Shares.

Following Second Admission, the Company's issued share capital will consist of 108,366,444 Ordinary Shares. There are no Ordinary Shares held in treasury. Therefore, in accordance with the FCA's Disclosure and Transparency Rule 5.6.1, the Company confirms that as at 15 November 2019, the total number of voting rights in the Company will be 108,366,444. Following Second Admission, this figure may be used by shareholders as the denominator for the calculations by which they determine whether they are required to notify their interest in, or a change to their interest in, C4XD under the Disclosure Guidance and Transparency Rules.

The capitalised terms used in this announcement have the meaning as defined in the announcement published by the Company at 7 a.m. on 24 October 2019 unless otherwise stated.

Market Abuse Regulation:

This announcement is released by C4X Discovery Holdings plc and contains inside information for the purposes of the Market Abuse Regulation (EU) 596/2014 (“**MAR**”) and is disclosed in accordance with the Company’s obligations under Article 17 of MAR.

The person responsible for arranging the release of this information is Clive Dix, CEO of the Company.

For further information, please contact:

C4X Discovery Holdings plc

Clive Dix, Chief Executive Officer 07801 865 803

Panmure Gordon (UK) Limited (NOMAD) 020 7886 2500

Freddy Crossley, Emma Earl (Corporate Finance)
James Stearns (Corporate Broking)

Consilium Strategic Communications

Mary-Jane Elliott, Matthew Neal, Chris Gardner 0203 709 5700

About C4X Discovery

C4X Discovery (C4XD) aims to create the world's most productive Drug Discovery engine by using cutting-edge technologies and expertise to efficiently deliver best-in-class small-molecule medicines to clinical partners for the benefit of patients. The Company's business model focuses on replenishing big pharma discovery pipelines and driving returns through revenue generating pre-clinical licensing deals. In 2018, C4XD successfully out-licensed a pre-clinical programme in addictive disorders to Indivior in a deal worth up to \$294m.

C4XD has a state-of-the-art suite of proprietary technologies across the Drug Discovery process and accesses further innovative capabilities and expertise through its growing network of partners. The Company is actively advancing its diverse pre-clinical discovery portfolio which is focused on inflammation, neurodegeneration and oncology (including immuno-oncology). Opportunities to maximise value from the portfolio are proactively driven by C4XD's commercial division. The Company is led by a highly experienced management team and Board who have delivered significant value creation within the healthcare sector.

For additional information please go to: www.c4xdiscovery.com

IMPORTANT NOTICES

Panmure Gordon (UK) Limited, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority (the "FCA"), is acting as Nominated Adviser and broker to the Company for the purposes of the AIM Rules for Companies and the AIM Rules for Nominated Advisers in connection with the Placing and is not acting for, and will not be responsible to, any person other than the Company for providing the protections afforded to customers of Panmure Gordon (UK) Limited or for advising any other person on any transaction or arrangement referred to in this Announcement.

--ENDS--